Relay Therapeutics

A three way hybrid in which machine learning is integral but not the differentiating insight. What distinguishes Relay is a scientific thesis about protein motion, executed through molecular dynamics simulation and experimental structural biology, with machine learning applied to the resulting data. The company's own description leads with conformational dynamics and with synthesising full length proteins through protein engineering, and positions machine learning as components of the Dynamo platform fed by screening data rather than as the platform itself. Machine learning is genuinely load bearing, most explicitly in the REL-DEL DNA encoded library capability which the company describes as machine learning powered and which the ZebiAI acquisition strengthened. Graded alongside Schrodinger and XtalPi as physics and experiment anchored rather than model led.

Oversight is structural and reciprocal by design: computational predictions generate hypotheses that are tested in activity based, ligand centric and computational screens, and the resulting experimental data feeds back into the machine learning components. Neither half runs unchecked, which is the intended shape of the platform rather than a control added afterwards. Held at B because no confidence thresholds, hit rate disclosures or documented decision gates between computational output and synthesis commitment were located.

The scientific thesis is explained clearly and the computational method is not. Company materials describe the three phases of motion based drug design, the role of full length protein synthesis in characterising conformational dynamics, and REL-DEL in outline. What was not located in this review is any model architecture description, benchmark, prediction accuracy figure or peer reviewed methods paper for the machine learning components. A further caution for diligence: much of the circulating technical detail about this platform originates in secondary commentary and aggregator profiles rather than company or peer reviewed sources, so a reader can easily mistake third party description for company disclosure.

Genuinely clinical stage, which places it ahead of most of this category, with multiple oncology programmes in trials and RLY-2608, a mutant selective PI3K alpha inhibitor for breast cancer, reported as the most advanced and reported to have produced tumour responses in patients who had progressed on prior PI3K therapy. Unlike several peers the clinical assets are platform originated rather than in licensed. Held at B rather than A on evidence provenance: the specific clinical results located in this review came largely from secondary coverage rather than from company releases or peer reviewed publication, so a buyer should confirm current programme status and data directly from company filings before relying on it. No approval exists.

Not applicable in the provider sense and rated accordingly rather than penalized. The platform operates on protein structures, simulation output and screening data with no patient records in the discovery workflow. Human subject protection in the ongoing oncology trials runs through trial protocol and site institutional review board oversight rather than vendor policy.

Not applicable. The company is a clinical stage therapeutics developer rather than a business associate of covered entities handling protected health information.

No SOC 2, ISO 27001 or equivalent attestation was located and no trust center was found. As a Nasdaq registrant the company carries disclosure control and cybersecurity risk reporting obligations, which is an indirect assurance mechanism rather than a security attestation and should not be conflated with one.

Correctly structured, with the Dynamo platform not presented as a regulated device and regulatory activity at the asset level. Multiple small molecule oncology programmes are in clinical trials under active INDs, with the most advanced reported in Phase 2. No approval has been obtained and no breakthrough or expedited designation was located in this review.

No AI governance framework or bias disclosure was located. The domain relevant question is narrower here than for purely data driven peers, because a physics simulation of protein motion is anchored to the target rather than to historical chemistry and is therefore less exposed to inheriting past medicinal chemistry preferences. The exposure that remains sits in the machine learning components trained on DNA encoded library screening data, which carry the chemical coverage limits of those libraries, so performance would be expected to differ between chemical space the libraries sample well and space they do not. No analysis of that was located.

Not applicable. This is a discovery and clinical development organization with no provider workflow surface and no EHR touchpoint.

Not applicable in the software sense. Dynamo is operated internally and coupled to the company's own protein engineering and structural biology capability rather than licensed to customers, so tenancy and residency questions do not arise for a counterparty. Partnerships such as the December 2023 X-Chem agreement bring external screening capability inward rather than pushing the platform outward.

Public listing on Nasdaq under RLAY means financial statements, programme status and risk factors are filed on a regular cadence and are inspectable by anyone, which is the baseline this index credits. Held at B rather than A because no segment level economics, partnership deal terms or platform commercial disclosure of the kind Schrodinger, XtalPi and Generate:Biomedicines provide was located in this review, and because the company sells no platform access, so the only commercial surface is the equity and the pipeline behind it. The X-Chem partnership was announced without disclosed economics.

Concentrated by design. Modality is small molecules only, and the disclosed therapeutic focus is precision oncology with additional reported work in fibrosis and genetic disease. The platform thesis narrows scope further in a way worth understanding: motion based design is most valuable against targets whose conformational dynamics gate druggability, which is a specific subset of hard targets rather than a general capability, and the company positions it that way rather than claiming universal applicability.